No Data
No Data
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination With Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
Guggenheim Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $12
Express News | Guggenheim Reiterates Buy on Compass Therapeuticsto Buy
Compass Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.
Compass Therapeutics' Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating
Express News | D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target